Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 4
1(25.0%)
Early Phase 1
1(25.0%)
4Total
Phase 2(2)
Phase 4(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04105231Phase 2Active Not Recruiting

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

Role: collaborator

NCT06062953Phase 2Recruiting

Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia

Role: collaborator

NCT05762783Completed

The Importance of Sleep for Diabetes Associated Tasks and Outcomes

Role: collaborator

NCT03535636Completed

Sleep Impairments in Refugees Diagnosed With PTSD

Role: collaborator

NCT03576664Early Phase 1Completed

Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans

Role: collaborator

NCT02761161Phase 4Completed

Treatment of Sleep Disturbances in Trauma-affected Refugees

Role: collaborator

All 6 trials loaded